Curis Inc (CRIS) — Institutional Holders Breakdown (Q2 2026)

Biotech Curis Inc. said Nasdaq confirmed it has regained compliance with the bid price listing rule (Rule 5550(a)(2)) and is in full compliance with the terms of its Nasdaq hearings panel. As a result, Curis avoids an immediate delisting, but it is now under a one-year discretionary panel monitor. If it falls out of compliance again during that period, Nasdaq would start delisting proceedings and Curis would have to go back to a hearings panel, without being allowed to submit a compliance plan or get extra time.

Curis Inc (CRIS) filed an 8-K on July 2, 2026, disclosing a material modification to the rights of security holders. The specifics are provided in Item 5.03, which is incorporated by reference.

Curis Inc. held a special meeting on June 25, 2026, where stockholders approved a charter amendment authorizing a reverse stock split. The Board then set the ratio at 1-for-20. This means every 20 existing shares will be combined into one, reducing the total number of outstanding shares.

Curis Inc (ticker: CRIS) filed a certificate of amendment to its articles of incorporation to effect a previously disclosed reverse stock split. The reverse split will become effective on July 2, 2026, at 5:00 PM ET, and the common stock will begin trading on Nasdaq on a split-adjusted basis at market open on July 6, 2026. The ticker symbol remains 'CRIS', but the CUSIP number changes to 231269408.

AI summary pending